22:6 PE, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, chloroform | 123284-81-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 22:6 PE, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, chloroform
• 英文别名: 2-azaniumylethyl [(2R)-2,3-bis[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy]propyl] phosphate
• CAS: 123284-81-1
• 化学式: C49H74NO8P
• 分子量: 836.1
• InChiKey: RBDNSJMXMWTPCS-NYUVKXDYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.6
• 重原子数：
  59
• 可旋转键数：
  39
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  139
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Compositions and methods for delivery of agents
  申请人：ModernaTX, Inc.

  公开号：US10207010B2

  公开（公告）日：2019-02-19

  This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

  本公开提供了改进的脂基组合物（包括脂质纳米颗粒组合物）及其使用方法，用于在体内递送包括核酸和蛋白质在内的制剂。这些组合物不会加速血液清除，而且在体内具有更好的毒性特征。
• Gas-filled stabilized particles and methods of use
  申请人：Children's Medical Center Corporation

  公开号：US10577554B2

  公开（公告）日：2020-03-03

  Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described.

  本文提供了各种充满气体的颗粒，这些颗粒具有封装气体的稳定膜。此外，还介绍了药物组合物、使用和处理方法以及制备方法。
• Immunomodulatory therapeutic MRNA compositions encoding activating oncogene mutation peptides
  申请人：ModernaTX, Inc.

  公开号：US10881730B2

  公开（公告）日：2021-01-05

  The disclosure features immunomodulatory therapeutic compositions of an mRNA encoding an activating oncogene mutation peptide and an mRNA encoding a polypeptide that enhances immune responses to the activating oncogene mutation peptide, for example an mRNA encoding an immune potentiator. The disclosure also features methods of using the same, for example, to stimulate anti-cancer immune responses.

  本发明的特征是由编码活化癌基因突变肽的mRNA和编码可增强对活化癌基因突变肽的免疫应答的多肽的mRNA（例如编码免疫增强剂的mRNA）组成的免疫调节治疗组合物。 本公开内容还包括使用相同方法，例如，刺激抗癌免疫反应的方法。
• Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
  申请人：ModernaTX, Inc.

  公开号：US11001861B2

  公开（公告）日：2021-05-11

  The invention relates to mRNA therapy for the treatment of galactosemia type 1 (Gal-1). mRNAs for use in the invention, when administered in vivo, encode human galactose-1-phosphate uridylyltransferase (GALT), isoforms thereof, functional fragments thereof, and fusion proteins comprising GALT. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GALT expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GALT activity in subjects, namely galactose-1-phosphate (Gal-1-P).

  本发明涉及用于治疗1型半乳糖血症（Gal-1）的mRNA疗法。用于本发明的mRNA在体内给药时，编码人半乳糖-1-磷酸尿苷酰转移酶（GALT）、其异构体、其功能片段以及包含GALT的融合蛋白。本发明的 mRNA 最好封装在脂质纳米颗粒（LNPs）中，以便在给药时有效地传递到受试者的细胞和/或组织中。本发明的 mRNA 疗法可增加和/或恢复受试者体内不足的 GALT 表达和/或活性水平。
• GAS-FILLED STABILIZED PARTICLES AND METHODS OF USE
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US20160030596A1

  公开（公告）日：2016-02-04

  Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described.